472 related articles for article (PubMed ID: 20653361)
1. Management of drug and food interactions with azole antifungal agents in transplant recipients.
Dodds-Ashley E
Pharmacotherapy; 2010 Aug; 30(8):842-54. PubMed ID: 20653361
[TBL] [Abstract][Full Text] [Related]
2. Frequency of potential azole drug-drug interactions and consequences of potential fluconazole drug interactions.
Yu DT; Peterson JF; Seger DL; Gerth WC; Bates DW
Pharmacoepidemiol Drug Saf; 2005 Nov; 14(11):755-67. PubMed ID: 15654717
[TBL] [Abstract][Full Text] [Related]
3. Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice.
Lempers VJ; Martial LC; Schreuder MF; Blijlevens NM; Burger DM; Aarnoutse RE; Brüggemann RJ
Curr Opin Pharmacol; 2015 Oct; 24():38-44. PubMed ID: 26218924
[TBL] [Abstract][Full Text] [Related]
4. Azole antimycotics and drug interactions in the perioperative period.
Saari TI; Olkkola KT
Curr Opin Anaesthesiol; 2010 Aug; 23(4):441-8. PubMed ID: 20610983
[TBL] [Abstract][Full Text] [Related]
5. Oral azole drugs as systemic antifungal therapy.
Como JA; Dismukes WE
N Engl J Med; 1994 Jan; 330(4):263-72. PubMed ID: 8272088
[TBL] [Abstract][Full Text] [Related]
6. New generation azole antifungals in clinical investigation.
Girmenia C
Expert Opin Investig Drugs; 2009 Sep; 18(9):1279-95. PubMed ID: 19678798
[TBL] [Abstract][Full Text] [Related]
7. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients.
Harnicar S; Adel N; Jurcic J
J Oncol Pharm Pract; 2009 Sep; 15(3):175-82. PubMed ID: 19282418
[TBL] [Abstract][Full Text] [Related]
8. Prophylactic antifungal agents used after lung transplantation.
Marino E; Gallagher JC
Ann Pharmacother; 2010 Mar; 44(3):546-56. PubMed ID: 20179260
[TBL] [Abstract][Full Text] [Related]
9. Dosing algorithm for concomitant administration of sirolimus, tacrolimus, and an azole after allogeneic hematopoietic stem cell transplantation.
Peksa GD; Schultz K; Fung HC
J Oncol Pharm Pract; 2015 Dec; 21(6):409-15. PubMed ID: 24938293
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological considerations for azole antifungal drug management in cystic fibrosis lung transplant patients.
Billaud EM; Guillemain R; Berge M; Amrein C; Lefeuvre S; Louët AL; Boussaud V; Chevalier P
Med Mycol; 2010 Nov; 48 Suppl 1():S52-9. PubMed ID: 21067331
[TBL] [Abstract][Full Text] [Related]
11. Difference in immunosuppressant dose requirement when transitioning to isavuconazole from other azoles in thoracic transplant recipients.
Kozuch JM; Burt C; Afshar K; Aslam S; Yung G; Mariski M; Golts E; Feist A
Transpl Infect Dis; 2024 Feb; 26(1):e14209. PubMed ID: 38059638
[TBL] [Abstract][Full Text] [Related]
12. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
Brüggemann RJ; Alffenaar JW; Blijlevens NM; Billaud EM; Kosterink JG; Verweij PE; Burger DM
Clin Infect Dis; 2009 May; 48(10):1441-58. PubMed ID: 19361301
[TBL] [Abstract][Full Text] [Related]
13. Azole antifungals: 35 years of invasive fungal infection management.
Allen D; Wilson D; Drew R; Perfect J
Expert Rev Anti Infect Ther; 2015 Jun; 13(6):787-98. PubMed ID: 25843556
[TBL] [Abstract][Full Text] [Related]
14. Voriconazole pharmacokinetic variability in cystic fibrosis lung transplant patients.
Berge M; Guillemain R; Boussaud V; Pham MH; Chevalier P; Batisse A; Amrein C; Dannaoui E; Loriot MA; Lillo-Le Louet A; Billaud EM
Transpl Infect Dis; 2009 Jun; 11(3):211-9. PubMed ID: 19302272
[TBL] [Abstract][Full Text] [Related]
15. Changing strategies for the management of invasive fungal infections.
Rapp RP
Pharmacotherapy; 2004 Feb; 24(2 Pt 2):4S-28S; quiz 29S-32S. PubMed ID: 14992487
[TBL] [Abstract][Full Text] [Related]
16. Antifungal prophylaxis and therapy in patients with hematological malignancies and hematopoietic stem cell transplant recipients.
Almyroudis NG; Segal BH
Expert Rev Anti Infect Ther; 2010 Dec; 8(12):1451-66. PubMed ID: 21133669
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic interaction between everolimus and antifungal triazoles in a liver transplant patient.
Pea F; Baccarani U; Tavio M; Cojutti P; Adani GL; Londero A; Baraldo M; Franceschi L; Furlanut M; Viale P
Ann Pharmacother; 2008 Nov; 42(11):1711-6. PubMed ID: 18812562
[TBL] [Abstract][Full Text] [Related]
18. Primary antifungal prophylaxis in hematopoietic stem cell transplant recipients: clinical implications of recent studies.
Marr KA
Curr Opin Infect Dis; 2008 Aug; 21(4):409-14. PubMed ID: 18594294
[TBL] [Abstract][Full Text] [Related]
19. A new era of antifungal therapy.
Wingard JR; Leather H
Biol Blood Marrow Transplant; 2004 Feb; 10(2):73-90. PubMed ID: 14750074
[TBL] [Abstract][Full Text] [Related]
20. Clinically relevant drug interactions of current antifungal agents.
Gubbins PO; Heldenbrand S
Mycoses; 2010 Mar; 53(2):95-113. PubMed ID: 20002883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
